Feedback
Urticaria-Inducing Activity with Thyroid Antibodies and Stimulating Hormone
2005415
Ordering Recommendation

Screen for possible thyroid autoimmunity in individuals with suspected chronic urticaria.

Mnemonic
UIAT
Methodology
Semi-Quantitative Ex Vivo Challenge/Cell Culture/Quantitative Enzyme-Linked Immunosorbent Assay/Quantitative Chemiluminescent Immunoassay
Performed
Mon, Fri
Reported
2-6 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Patients taking calcineurin inhibitors should stop their medication 72 hours prior to draw. Patients on prednisone should be off their medication for 2 weeks prior to draw. 
Collect
Plain red. 
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport tube and freeze immediately (Min: 0.5 mL) AND transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL) 
Storage/Transport Temperature
First Specimen: CRITICAL FROZEN. Separate specimens must be submitted for this multiple test panel.
Second Specimen:
Refrigerated. 
Unacceptable Conditions
Specimens other than serum. Contaminated, grossly hemolyzed, or lipemic specimens. 
Remarks
 
Stability
First Specimen: After separation from cells: Ambient: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Second Specimen: After separation from cells: Ambient: 24 hours; Refrigerated: 1 Week; Frozen: 6 months 
Reference Interval
By report
Interpretive Data
Refer to report.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
1) Chronic urticaria (CU) is a common and complex dermatological condition that is suspected when patients experience persistent hives for over 6 weeks.  No published evidence of an exogenous allergen as the cause of this disorder exists. About 45 percent of cases have autoantibodies directed against either basophil or mast cell-associated IgE or the high affinity IgE-Fc receptor (Fc epsilon R1 alpha) (Clin Exp Allergy 2009; 39: 777-87). 

2) The presence of histamine releasing factors (including but not limited to IgE and Fc epsilon R1 alpha-specific autoantibodies) in the patient serum can be indirectly determined by evaluating basophil/mast cell activation status using histamine release assays, autologous serum-skin test, and flow cytometric measurement of the basophil and mast cell-specific marker CD203c. Serum from CU patients can activate donor basophils, which induces histamine release and CD203c upregulation (J Allergy Clin Immunol 2006; 117: 1430-4).
CPT Code(s)
86352; 86800; 84443; 86376
Components
Component Test Code*Component Chart NameLOINC
0050075Thyroid Peroxidase (TPO) Antibody8099-4
0050105Thyroglobulin Antibody8098-6
0070145Thyroid Stimulating Hormone3016-3
2005414Urticaria-Inducing Activity63369-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Chronic Urticaria
  • Chronic Urticaria Panel
  • urticaria-inducing activity, TPO, TSH, Tg antibodies